Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06171152 · ClinicalTrials.gov registry record · Early Phase 1

Study of Liraglutide (A Weight Loss Drug) in High Risk Obese Participants With Cognitive and Memory Issues

A Early Phase 1 study of Obesity and Multiple Sclerosis, sponsored by University of Chicago.

Recruiting
Registry status
Early Phase 1
Development phase
30
Enrollment target
1
Study location

NCT06171152 is a Early Phase 1 study of Obesity and Multiple Sclerosis that is actively recruiting participants, run by University of Chicago. The registered enrollment target is 30 participants, below the 819-participant average among 1,053 other Obesity trials with a reported enrollment target (96% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06171152, a Early Phase 1 study of Obesity and Multiple Sclerosis, is actively recruiting participants, sponsored by University of Chicago.

RECRUITING
Registry status
Early Phase 1
Development phase
30 participants
Enrollment target
1
Study location

Study Summary

This study is for people who have multiple sclerosis, acute leukemia (in remission), or long-COVID and a Body Mass Index over 27 and may struggle with cognitive issues such as remembering information, concentrating, or making decisions that affect everyday life. By doing this study, researchers hope to learn how liraglutide (Saxenda®), a weight loss drug, affects levels of a certain disease marker in the body called Brain Derived Neurotrophic Factor (BDNF). Participation in this research will last about 21 weeks.

Conditions Studied

Obesity Multiple Sclerosis Long COVID Obese Obesity, Morbid Long Covid19 Acute Leukemia in Remission

Interventions

  • DRUG Liraglutide Pen Injector [Saxenda]
  • OTHER Medication Diary

Study Locations (1)

Illinois

  • University of Chicago Medicine Comprehensive Cancer Center - Chicago

Trial Details

FieldValue
Enrollment Target 30 participants
Start Date 2024-01-26
Est. Completion 2026-10-01
Phase Early Phase 1

Sponsor

University of Chicago

796 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06171152

The ClinicalTrials.gov registry entry for NCT06171152 describes a study currently listed as recruiting, categorized as Early Phase 1. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 819-participant average among 1,053 other Obesity trials with a reported enrollment target (96% lower). The listed sponsor is University of Chicago, which has 796 total studies on file at ClinicalTrials.gov.

The record links to 7 conditions, with Obesity appearing as the primary indexed condition, and to 2 interventions - of which Liraglutide Pen Injector [Saxenda] is the first listed.

NCT06171152 reports 1 study location spanning 1 distinct geographic area - top geographies include Illinois.

Frequently Asked Questions

What is clinical trial NCT06171152 about?

NCT06171152 is a clinical study titled "Study of Liraglutide (A Weight Loss Drug) in High Risk Obese Participants With Cognitive and Memory Issues". This study is for people who have multiple sclerosis, acute leukemia (in remission), or long-COVID and a Body Mass Index over 27 and may struggle with cognitive issues such as remembering information, concentrating, or making decisions that affect everyday life. By doing this study, researchers hop...

What is the current status of trial NCT06171152?

This trial is currently recruiting. It is a Early Phase 1 study. The enrollment target is 30 participants. The study started on 2024-01-26. Estimated completion is 2026-10-01.

What conditions does trial NCT06171152 study?

This clinical trial studies the following conditions: Obesity, Multiple Sclerosis, Long COVID, Obese, Obesity, Morbid.

What interventions are being tested in trial NCT06171152?

The interventions under investigation include: Liraglutide Pen Injector [Saxenda] (DRUG), Medication Diary (OTHER).

Who is sponsoring clinical trial NCT06171152?

This trial is sponsored by University of Chicago, which has 796 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06171152 being conducted?

This trial has 1 study location across Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Obesity

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Obesity

All registered trials for this condition

Multiple Sclerosis

All registered trials for this condition

Illinois

All trials with a study site in Illinois

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.